Category: Approval/Launch Region: Asia · China Company: Astrazeneca Pharmaceuticals China Co Ltd

China NMPA approves AstraZeneca & Daiichi Sankyos Enhertu to treat HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

By, Admin 1 min read
Share
China NMPA approves AstraZeneca & Daiichi Sankyos Enhertu to treat HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
AstraZeneca and Daiichi Sankyo

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!